These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38972483)

  • 1. Targeted immunotherapy for moderate-to-severe palmoplantar pustulosis: a network meta-analysis of randomized controlled trials.
    Tsai YC; Hsu FL; Tsai TF
    J Am Acad Dermatol; 2024 Jul; ():. PubMed ID: 38972483
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
    Terui T; Okubo Y; Kobayashi S; Sano S; Morita A; Imafuku S; Tada Y; Abe M; Yaguchi M; Uehara N; Handa T; Tanaka M; Zhang W; Paris M; Murakami M
    Am J Clin Dermatol; 2023 Sep; 24(5):837-847. PubMed ID: 37233897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal treatments and outcome measures of palmoplantar pustulosis: A systematic review and network meta-analysis-based comparison of treatment efficacy.
    Fukasawa T; Yamashita T; Enomoto A; Yoshizaki-Ogawa A; Miyagawa K; Sato S; Yoshizaki A
    J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):281-288. PubMed ID: 37684049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apremilast in Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Meta-analysis.
    Spencer RK; Elhage KG; Jin JQ; Davis MS; Hakimi M; Bhutani T; Liao W
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):437-451. PubMed ID: 36609960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/Pharmacodynamic Analysis of Guselkumab for Treatment of Palmoplantar Pustulosis: Clinical Implications of Guselkumab Dose, Disease Severity, and Smoking in Japanese Patients.
    Iwaki Y; Shibata S; Hu C
    J Clin Pharmacol; 2022 Feb; 62(2):182-189. PubMed ID: 34382209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local injection of micro-dose anti-interleukin-17A antibody for palmoplantar pustulosis: A real-world study.
    Xia R; Liu J; Gao Y; Diao Z; Chen D; Zhou C; Zhang Z; Yin Z
    Clin Immunol; 2023 Aug; 253():109694. PubMed ID: 37433424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for chronic palmoplantar pustulosis.
    Obeid G; Do G; Kirby L; Hughes C; Sbidian E; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011628. PubMed ID: 31958161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis.
    Bissonnette R; Maari C; Tsianakas A; Reid D; McCutchan S; Baumgartner S; Mackay J; Bhakta N
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):2179-2193. PubMed ID: 34716902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of anti-interleukin-17A biological agents for palmoplantar psoriasis and palmoplantar pustulosis: A network meta-analysis.
    Xia R; Diao Z; Chen D; Wang Y; Zhou C; Gao Y; Yin Z
    Int Immunopharmacol; 2024 Mar; 130():111716. PubMed ID: 38417367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Efficacy and Safety of Apremilast and Methotrexate in Patients with Palmoplantar Psoriasis: A Randomized Controlled Trial.
    Kt S; Thakur V; Narang T; Dogra S; Handa S
    Am J Clin Dermatol; 2021 May; 22(3):415-423. PubMed ID: 33712987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 308-nm excimer light is effective for palmoplantar pustulosis regardless of the presence or absence of focal infection: Single-center real-world experience of treatment for palmoplantar pustulosis.
    Niimura Y; Kamata M; Ishikawa T; Nagata M; Ito M; Watanabe A; Egawa S; Uchida H; Hiura A; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Tada Y
    J Dermatol; 2024 Jul; 51(7):977-984. PubMed ID: 38483008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial.
    Okubo Y; Kobayashi S; Murakami M; Sano S; Kikuta N; Ouchi Y; Terui T
    Am J Clin Dermatol; 2024 Jul; ():. PubMed ID: 38954226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refractory Palmoplantar Pustulosis Successfully Treated with JAK Inhibitor Tofacitinib: A Case Series.
    Xu Q; Wang X; Yang A; Wei G
    Infect Drug Resist; 2023; 16():5165-5172. PubMed ID: 37581169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT).
    Cro S; Cornelius VR; Pink AE; Wilson R; Pushpa-Rajah A; Patel P; Abdul-Wahab A; August S; Azad J; Becher G; Chapman A; Dunnil G; Ferguson AD; Fogo A; Ghaffar SA; Ingram JR; Kavakleiva S; Ladoyanni E; Leman JA; Macbeth AE; Makrygeoegou A; Parslew R; Ryan AJ; Sharma A; Shipman AR; Sinclair C; Wachsmuth R; Woolf RT; Wright A; McAteer H; Barker JNWN; Burden AD; Griffiths CEM; Reynolds NJ; Warren RB; Lachmann HJ; Capon F; Smith CH;
    Br J Dermatol; 2021 Aug; 186(2):245-56. PubMed ID: 34411292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.
    Huang IH; Wu PC; Chiu HY; Huang YH
    Am J Clin Dermatol; 2024 May; 25(3):347-358. PubMed ID: 38438782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis.
    Benzian-Olsson N; Dand N; Chaloner C; Bata-Csorgo Z; Borroni R; Burden AD; Cooper HL; Cornelius V; Cro S; Dasandi T; Griffiths CEM; Kingo K; Koks S; Lachmann H; McAteer H; Meynell F; Mrowietz U; Parslew R; Patel P; Pink AE; Reynolds NJ; Tanew A; Torz K; Trattner H; Wahie S; Warren RB; Wright A; Barker JN; Navarini AA; Smith CH; Capon F;
    JAMA Dermatol; 2020 Nov; 156(11):1216-1222. PubMed ID: 32936291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study.
    Reich K; Graff O; Mehta N
    Br J Dermatol; 2016 Jun; 174(6):1277-81. PubMed ID: 26800106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
    Sanchez IM; Sorenson E; Levin E; Liao W
    Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study.
    Burden AD; Bissonnette R; Navarini AA; Murakami M; Morita A; Haeufel T; Ye B; Baehner F; Terui T
    Dermatol Ther (Heidelb); 2023 Oct; 13(10):2279-2297. PubMed ID: 37731086
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.